GBR 12935 is an inhibitor of the dopamine transporter (DAT) that increases activation of DA receptors and is used to study DA signaling. This compound increases reward and reinforcement signaling, mimicking the activation of D1 and D2 receptors and increases in glutamate levels that occur during chronic administration of abused substances such as cocaine.
| Cas No. | 67469-81-2 |
|---|---|
| Purity | ≥98% |
| Formula | C28H36Cl2N2O |
| Formula Wt. | 487.51 |
| IUPAC Name | 1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | G0668 Info Sheet PDF |
|---|
Root DH, Hoffman AF, Good CH, et al. Norepinephrine activates dopamine D4 receptors in the rat lateral habenula. J Neurosci. 2015 Feb 25;35(8):3460-9. PMID: 25716845.
Zuo W, Chen L, Wang L, et al. Cocaine facilitates glutamatergic transmission and activates lateral habenular neurons. Neuropharmacology. 2013 Jul;70:180-9. PMID: 23347950.
Janowsky A, Berger P, Vocci F, et al. Characterization of sodium-dependent [3H]GBR-12935 binding in brain: a radioligand for selective labelling of the dopamine transport complex. J Neurochem. 1986 Apr;46(4):1272-6. PMID: 3081686.
